In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes

Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology

Volumn 94, Issue 3, 2008, Pages 463-470

  Galgóczy, László ^a   Papp, Tamás ^a   Pócsi, István ^b   Hegedűs, Nikoletta ^b   Vágvölgyi, Csaba ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Drug interaction; Fluconazole; Microsporum; PAF; Trichophyton

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; PENICILLIUM CHRYSOGENUM ANTIFUNGAL PROTEIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONIDIUM; CONTROLLED STUDY; DERMATOPHYTE; DRUG POTENTIATION; FUNGAL SPORE GERMINATION; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; GROWTH INHIBITION; IN VITRO STUDY; INHIBITION KINETICS; MICROSPORUM CANIS; MICROSPORUM GYPSEUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS;

ARTHRODERMA BENHAMIAE; ARTHRODERMA GYPSEUM; ARTHRODERMATACEAE; FUNGI; MICROSPORUM; MICROSPORUM CANIS; PENICILLIUM CHRYSOGENUM; TRICHOPHYTON; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS;

EID: 50949124517     PISSN: 00036072     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10482-008-9263-x     Document Type: Article

References (33)

1. Abecassis S, Roujeau J-C, Bocquet H, Copie-Bergman C, Radier C, Revuz J, Cosnes A (2004) Severe sialadenitis: A new complication of drug reaction with eosinophilia and systemic symptoms. J Am Acad Dermatol 51:827-830
2. Aksakal BA, Özsoy E, Arnavut Ö, Gürer MA (2003) Oral terbinafine-induced bullous pemphigoid. Ann Pharmacother 37:1625-1627
3. Bennett ML, Jorizzo JL, White WL (1999) Generalized pustular eruptions associated with oral terbinafine. Int J Dermatol 38:596-600
4. Fernández-Torres B, Carrillo AJ, Martin E, del Palaco A, Moore MK, Valverde A, Serrano M, Guarro J (2001) In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 45:2524-2528
5. Fernández-Torres B, Cabanes FJ, Carrillo-Munoz AJ, Esteban A, Inza I, Abarca L, Guarro J (2002) Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 40:3999-4003
6. Galgóczy L, Papp T, Leiter É, Marx F, Pócsi I, Vágvölgyi C (2005) Sensitivity of different Zygomycetes to the Penicillium chrysogenum antifungal protein (PAF). J Basic Microbiol 45:136-141
7. Galgóczy L, Papp T, Lukács G, Leiter É, Pócsi I, Vágvölgyi C (2007) Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett 207:109-115
8. Ghannoum MA, Chaturvedi V, Espinel-Ingroff A, Pfaller MA, Rinaldi MG, Lee-Yang W, Warnock DW (2004) Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J Clin Microbiol 42:2977-2979
9. Ghannoum M, Isham N, Sheehan D (2006a) Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial. J Clin Microbiol 44:2579-2581
10. Ghannoum MA, Arthington-Skaggs B, Chaturvedi V, Espinel-Ingroff A, Pfaller MA, Rennie R, Rinaldi MG, Walsh TJ (2006b) Interlaboratory study of quality control isolates for a broth microdilution method (Modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals. J Clin Microbiol 44:4354-4356
11. Gupta AK, Porges AJ (1998) Hypersensitivity syndrome reaction to oral terbinafine. Aust J Dermatol 39:171-172
12. Gupta AK, Lynde CW, Lauzon GJ, Mehlmauer MA, Braddock SW, Miller CA, Del Rosso JQ, Shear NH (1998) Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol 138:529-532
13. Hall AP, Tate B (2000) Acute generalized exanthematous pustulosis associated with oral terbinafine. Aust J Dermatol 41:42-45
14. Jacobi U, Engel K, Patzelt A, Worm M, Sterry W, Lademann J (2007) Penetration of pollen proteins into the skin. Skin Pharmacol Physiol 20:297-304
15. Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA (2000) Antifungal susceptibility testing of dermatophytes: Establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 38:341-344
16. Kaiserer L, Oberparleiter C, Weiler-Görz R, Burgstaller W, Leiter É, Marx F (2003) Characterization of the Penicillium chrysogenum antifungal protein PAF. Arch Microbiol 180:204-210
17. Kim B-S, Jang H-S, Jwa S-W, Jang B-S, Kim M-B, Oh C-K, Kwon Y-W, Kwon K-S (2007) Generalized pustular psoriasis and hepatic dysfunction associated with oral terbinafine therapy. J Korean Med Sci 22:167-169
18. Leiter É, Szappanos H, Oberparleiter C, Kaiserer L, Csernoh L, Pusztahelyi T, Emri T, Pócsi I, Salvenmoser W, Marx F (2005) Antifungal protein PAF severely affects the integrity of the plasma membrane of Aspergillus nidulans and induces an apoptosis-like phenotype. Antimicrob Agents Chemother 49:2445-2453
19. Marx F (2004) Small, basic antifungal proteins secreted from filamentous ascomycetes: A comparative study regarding expression, structure, function and potential application. Appl Microbiol Biotechnol 65:133-142
20. Marx F, Haas H, Reindl M, Stoffler G, Lottspeich F, Redl B (1995) Cloning, structural organization and regulation of expression of the Penicillium chrysogenum paf gene encoding an abundantly secreted protein with antifungal activity. Gene 167:167-171
21. Marx F, Binder U, Leiter É, Pócsi I (2007) The Penicillium chrysogenum antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studies. Cell Mol Life Sci 65:445-454
22. McKellar G, Porter D, Burden D (2004) Terbinafine as a cause of cutaneous lupus erythematosus. Rheumatology 43:249
23. Moreno AB, del Pozo ÁM, Borja M, San Segudo B (2003) Activity of the antifungal protein from Aspergillus giganteus against Botrytis cinerea. Phytopathology 93:1344-1353
24. Odds FC, Brown AJP, Gow NAR (2003) Antifungal agents: Mechanisms of action. Trends Microbiol 11:272-279
25. Rogalski C, Hürlimann A, Burg G, Wüthrich B, Kempf W (2001) Drug reaction to terbinafine simulating an acute generalized exanthematous pustulosis. Hautarzt 52:444-448
26. Santos DA, Hamdan JS (2005) Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum. J Clin Microbiol 43:1917-1920
27. Santos DA, Barros MES, Hamdan JS (2006) Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J Clin Microbiol 44:98-101
28. Schopf R, Hettler O, Bräutigam M, Weidinger G, Kaben U, Mayser P, Res V (1999) Efficacy and tolerability of terbinafine 1% topical solution used for 1 week compared with 4 weeks clotrimazole 1% topical solution in the treatment of interdigital tinea pedis: A randomized, double-blind, multi-centre, 8-week clinical trial. Mycoses 42:415-420
29. Szappanos H, Szigeti GyP, Pál B, Rusznák Z, Szñcs G, Rajnavölgyi É, Balla J, Balla G, Nagy E, Leiter é, Pócsi I, Marx F, Csernoch L (2005) The Penicillium chrysogenum -derived antifungal peptide shows no toxic effects on mammalian cells in the intended therapeutic concentration. Naunyn-Schmiedebergs Arch Pharmacol 371:122-132
30. van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG (2001) Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome? Pharmacoepidemiol Drug Saf 10:135-142
31. Villars V, Jones TC (1989) Clinical efficacy and tolerability of terbinafine (Lamisil)-a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 14:124-127
32. Weitzman I, Summerbell RC (1995) The dermatophytes. Clin Microbiol Rev 8:240-259
33. Wildfeuer A, Faergemann J, Laufen H, Pfaff G, Zimmermann T, Seidl HP, Lach P (1994) Bioavailability of fluconazole in the skin after oral medication. Mycoses 37:127-130